Rezvoglar™ (insulin glargine-aglr) injection

3 mL (100 units/mL)

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is the route of administration for Rezvoglar™ (insulin glargine-aglr)?

Rezvoglar is administered as a subcutaneous injection.

US_cFAQ_REZ010_ROUTE_OF_ADMINISTRATION
US_cFAQ_REZ010_ROUTE_OF_ADMINISTRATION
en-US

Route of Administration

Administer Rezvoglar™ (insulin glargine-aglr) 100 units/mL subcutaneously into the abdominal area, thigh, or deltoid.1

Administration Instructions

Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis.1

Do not dilute or mix Rezvoglar with any other insulin or solution.1

Do not administer Rezvoglar intravenously or via an insulin pump.1

Route of Administration Versus Duration of Action

In patients with type 1 diabetes, after subcutaneous injection of another insulin glargine 100 units/mL product, the duration of action after abdominal, deltoid, or thigh administration was similar.1

Reference

1Rezvoglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Date of Last Review: February 02, 2022


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical